IP Library Patent Application 16592117
Patent Application
App. No. 16/592,117

CELL SUSPENSION AND USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/592,117
Abstract

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration.

Claims (23)

1 - 49 . (canceled)

50 . A method for treating a chronic wound in skin of a patient, comprising:

preparing an autologous cell suspension without in vitro culturing; and

administering the cell suspension to the chronic wound of the patient to promote tissue regeneration at the chronic wound.

51 . The method of claim 50 , wherein the chronic wound is a chronic ulcer.

52 . The method of claim 51 , wherein the chronic ulcer is a diabetic ulcer.

53 . The method of claim 51 , wherein the chronic ulcer is at least one selected from the group consisting of a venous ulcer, an arterial ulcer, and a mixed arterio-venous ulcer.

54 . The method of claim 50 , wherein the chronic wound is at least one selected from the group consisting of a neuropathic ulcer and a pressure sore.

55 . The method of claim 50 , wherein preparing the autologous cell suspension comprises obtaining a skin tissue sample from the patient, collecting a population of cells from the skin tissue sample, and mixing the population of cells with a nutrient solution to create the autologous cell suspension.

56 . The method of claim 55 , wherein collecting the population of cells comprises exposing the skin tissue sample to an enzyme to dissociate cellular layers in the skin tissue sample.

57 . The method of claim 56 , wherein the enzyme comprises trypsin or trypsin-EDTA.

58 . The method of claim 56 , wherein the enzyme comprises at least one selected from the group consisting of dispase, collagenase, thermolysin, pronase, hyaluronidase, elastase, papain, and pancreatin.

59 . The method of claim 55 , wherein collecting the population of cells comprises performing at least one selected from the group consisting of: scraping, mincing, cutting, perfusing, and grinding.

60 . The method of claim 55 , wherein the population of cells comprises viable cells from an epidermal layer and a dermal layer from the skin tissue sample.

61 . The method of claim 60 , wherein the population of cells comprises keratinocytes, melanocytes, and fibroblasts.

62 . The method of claim 55 , wherein the nutrient solution comprises at least one of Hartmann's solution and physiological saline.

63 . The method of claim 55 , wherein preparing the cell suspension further comprises exposing the population of cells to at least one exogenous agent.

64 . The method of claim 63 , wherein the at least one exogenous agent comprises platelet-enriched plasma.

65 . The method of claim 63 , wherein the at least one exogenous agent comprises at least one selected from the group consisting of: hyaluronic acid, heat shock proteins, growth factors, cytokines, and adipose stem cells.

66 . The method of claim 65 , wherein the heat shock proteins comprise at least one selected from the group consisting HSP90 and HSP90α.

67 . The method of claim 65 , wherein the growth factors comprise at least one selected from the group consisting of angiopoietins, epidermal growth factor, transforming growth factor-α, transforming growth factor-β, hepatocyte growth factor, vascular endothelial growth factor, platelet derived growth factor, fibroblast growth factor 1, fibroblast growth factor 2, insulin-like growth factor 1, insulin-like growth factor 2, connective tissue growth factor, and keratinocyte growth factor.

68 . The method of claim 50 , wherein administering the cell suspension is performed peri-operatively.

69 . The method of claim 50 , wherein administering the cell suspension comprise at least one selected from the group consisting of spraying, dripping, spreading, pipetting, painting, and injecting the cell suspension.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2026
From: ORCO IV LLC
To: AVITA MEDICAL AMERICAS, LLC
Reel/Frame 073473/0540 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2024
From: ORCO IV LLC
To: AVITA MEDICAL PTY LIMITED
Reel/Frame 066960/0046 →
SECURITY INTEREST Recorded Apr 1, 2024
From: AVITA MEDICAL AMERICAS, LLC
To: ORCO IV LLC
Reel/Frame 066960/0144 →
SECURITY INTEREST Recorded Dec 13, 2023
From: AVITA MEDICAL PTY LIMITED
To: ORCO IV LLC
Reel/Frame 065856/0614 →
CHANGE OF NAME Recorded Sep 13, 2021
From: AVITA MEDICAL LTD
To: AVITA MEDICAL PTY LIMITED
Reel/Frame 057497/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2020
From: QUICK, ANDREW; DOLPHIN, WILLIAM
To: AVITA MEDICAL LTD
Reel/Frame 052142/0597 →